If you suffered substantial losses and wish to serve as lead plaintiff of the Tempus AI class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected]. Lead plaintiff motions for the Tempus AI lawsuit must be filed with the court no later than August 12, 2025.
In this comprehensive and instructive guide, we will demystify the key rights and options common shareholders possess in a securities class action lawsuit like the Tempus AI lawsuit.
Read on to learn everything an investor needs to know about the lead plaintiff process in the Tempus AI class action lawsuit.
Allegations in the Tempus AI Class Action Lawsuit
Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI.
The Tempus AI class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded;
- The credibility and substance of Tempus AI’s joint venture with SoftBank Group Corporation was at risk because it gave the appearance of “round-tripping” capital to create revenue for Tempus AI;
- Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability;
- AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable “pass-through payment” via a joint agreement between it, Tempus AI, and Pathos AI, Inc.; and
- The above issues revealed weakness in core operations and revenue prospects.

The Tempus AI lawsuit further alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued research report on Tempus AI that raised numerous red flags over Tempus AI’s management, operations, and financial reporting. On this news, the price of Tempus AI stock fell more than 19%, according to the Tempus AI lawsuit.
The Lead Plaintiff Process in the Tempus AI Lawsuit
Under the Private Securities Litigation Reform Act of 1995 (PSLRA):
- Any investor who purchased and suffered losses in Tempus AI stock may seek appointment as lead plaintiff in the Tempus AI lawsuit.
- A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.
- A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit.
- The lead plaintiff can select a law firm of its choice to litigate the securities class action lawsuit.
- An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.



